Fresh2 (FRES): Debts to Book Capitalization

Brandmark of fresh2.co (FRES)

Fresh2 Group Limited is developing a digital medical diagnostics ecosystem, expanding its revenue base through IT services for clinics. The company optimizes agrologistics via data, connecting farmers with restaurants, and adheres to fundamental back-office environmental standards. The company's total debt-to-equity ratio confirms these foundations, where 0.00 represents the current metric level, demonstrating a balance between financial stability and profitability.

FRES Fresh2 Group Debt to Book Value Ratio (02/21/2024 - 01/04/2025)
Original product of Fresh2 Group Ltd

Fresh2 Group Limited operates in the high-tech B2B supply segment subject to strict regulatory control. This metric compares total liabilities to equity, reflecting the share of debt financing within the balance sheet structure. It determines the business's level of dependence on creditors and the risk of default during market volatility. The company's proprietary IT platform creates a sustainable barrier for competitors, reducing operational risks. By analyzing the financial stability indicator—debt-to-capitalization—an investor assesses the balance between security and the use of leverage for expansion.

Competitors of Fresh2 Group Limited

A - Debts to Book Capitalization|Debt to Book Value Ratio questdiagnostics.com DGX|Illumina - Debts to Book Capitalization|EXAS: Debts to Book Capitalization|Debt to Book Capitalization Ratio PerkinElmer|Bio-Rad Corp (BIO) - Debt to Book Value Ratio|NNNN (Anbio Biotechnology) - Debts to Book Capitalization|Debts to Book Capitalization SHC|Debt to Book Capitalization Ratio QuidelOrtho Corporation (QDEL)|Debt to Book Capitalization Ratio OPKO Health Inc OPK|CDNA: Debt to Book Value|Maravai - Debts to Book Value|Debt to Book Capitalization Ratio FLGT (Fulgent Genetics, Inc.)|LAB - Debts to Net Assets|Cytek Biosciences - Debts to Book Capitalization|OSUR (OraSure Technologies, Inc.) - Debts to Net Assets|XGN: Debt to Book Capitalization Ratio|Debts to Net Assets MDxHealth, Inc.|LUCD - Debts to Book Capitalization|Debts to Book Capitalization Ratio PRE (prenetics.com)|Debt to Book Capitalization Ratio Insight Molecular Diagnostics Inc|Debt to Net Assets Ratio Trinity Biotech PLC TRIB|PRPH (ProPhase) - Debts to Book Capitalization|AIMD: Debts to Book Value|Co-Diagnostics, Inc. - Debt to Book Capitalization Ratio|heartsciences.com (HSCS) - Debts to Net Assets|BMRA - Debts to Book Capitalization|Debt to Net Assets Ratio CDIO|Debt to Book Capitalization Ratio VRAX (Virax Biolabs Group Ltd)|BJDX (Bluejay Diagnostics Corp) - Debt to Book Value|Debt to Net Assets Ratio AWH (Aspira Women's Health)|Debts to Book Capitalization acceleratediagnostics.com|CNTG - Debt to Net Assets|Debt to Book Capitalization Ratio ENZ (Enzo Biochem, Inc.)|gtglabs.com (GENE) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio 23andMe Inc (ME)|Debts to Book Value PMD